Abstract
Caspofungin is the first echinocandin drug licensed for treatment of fungal infections. The drug is active in vitro and in animal models against both albicans and non-albicans Candida species and Aspergillus species. Results from clinical trials support its efficacy as a first-line therapy for patients with esophageal or invasive candidiasis and salvage therapy for patients with invasive aspergillosis. In all studies, caspofungin has been generally well tolerated; serious drug-related adverse events and adverse events leading to discontinuation of therapy have been infrequent.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
